--- title: "Beigene (BGNE.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/BGNE.US.md" symbol: "BGNE.US" name: "Beigene" industry: "Biotechnology" datetime: "2026-05-20T16:47:37.146Z" locales: - [en](https://longbridge.com/en/quote/BGNE.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/BGNE.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/BGNE.US.md) --- # Beigene (BGNE.US) ## Company Overview BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company’s clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: C > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-20T04:30:13.000Z **Overall: C (0.41)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 192 / 386 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock. **Multi Score**: C #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 49.14% | | | Net Profit YoY | 16.52% | | | P/B Ratio | 0.00 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 0.00 | | | Revenue | 3288831334.00 | | #### Multi Score Score: C | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -23.22% | E | | Profit Margin | -25.50% | E | | Gross Margin | 83.28% | A | | Revenue YoY | 49.14% | A | | Net Profit YoY | 16.52% | C | | Total Assets YoY | 5.55% | C | | Net Assets YoY | -8.32% | D | | Cash Flow Margin | 76.06% | C | | OCF YoY | 49.14% | A | | Turnover | 0.58 | B | | Gearing Ratio | 40.83% | C | ```chart-data:radar { "title": "Longbridge Financial Score - Beigene", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "49.14%", "rating": "" }, { "name": "Net Profit YoY", "value": "16.52%", "rating": "" }, { "name": "P/B Ratio", "value": "0.00", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "0.00", "rating": "" }, { "name": "Revenue", "value": "3288831334.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "C", "indicators": [ { "name": "ROE", "value": "-23.22%", "rating": "E" }, { "name": "Profit Margin", "value": "-25.50%", "rating": "E" }, { "name": "Gross Margin", "value": "83.28%", "rating": "A" }, { "name": "Revenue YoY", "value": "49.14%", "rating": "A" }, { "name": "Net Profit YoY", "value": "16.52%", "rating": "C" }, { "name": "Total Assets YoY", "value": "5.55%", "rating": "C" }, { "name": "Net Assets YoY", "value": "-8.32%", "rating": "D" }, { "name": "Cash Flow Margin", "value": "76.06%", "rating": "C" }, { "name": "OCF YoY", "value": "49.14%", "rating": "A" }, { "name": "Turnover", "value": "0.58", "rating": "B" }, { "name": "Gearing Ratio", "value": "40.83%", "rating": "C" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A | | 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A | | 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A | | 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A | ## Institutional View ### Analyst Rating Distribution ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 184.71 | | Highest Target | undefined | | Lowest Target | undefined | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BGNE.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BGNE.US/norm.md) - [Related News](https://longbridge.com/en/quote/BGNE.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BGNE.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**